PT - JOURNAL ARTICLE AU - Le, Jiao AU - Zhang, Lan AU - Zhao, Weihua AU - Zhu, Siyu AU - Lan, Chunmei AU - Kou, Juan AU - Zhang, Qianqian AU - Zhang, Yingying AU - Li, Qin AU - Chen, Zhuo AU - Fu, Meina AU - Montag, Christian AU - Zhang, Rong AU - Yang, Wenxu AU - Becker, Benjamin AU - Kendrick, Keith M. TI - Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial AID - 10.1101/2022.01.03.22268708 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.03.22268708 4099 - http://medrxiv.org/content/early/2022/04/08/2022.01.03.22268708.short 4100 - http://medrxiv.org/content/early/2022/04/08/2022.01.03.22268708.full AB - There are currently no approved drug interventions for social behavior dysfunction in autism spectrum disorder (ASD). Previous trials investigating effects of daily intranasal oxytocin treatment have reported inconsistent results and have not combined it with positive social interaction. However, In two preclinical studies we established that treatment every-other-day rather than daily is more efficacious in maintaining neural and behavioral effects by reducing receptor desensitization. We aimed to establish whether a 6-week intranasal oxytocin compared with placebo treatment, followed by a period of positive social interaction, would produce reliable symptom improvements in children with ASD. A pilot double-blind, randomized, crossover design trial was completed including 41 children with ASD aged 3-8 years. Primary outcomes were the Autism Diagnostic Observation Schedule-2 (ADOS-2) and social responsivity scale-2 (SRS-2). Secondary measures included cognitive, autism and caregiver-related questionnaires and social attention assessed using eye-tracking. Significant improvements were found for oxytocin relative to placebo in primary outcome measures (total ADOS-2 and SRS-2 scores, ps < 0.001) and in behavioral adaptability and repetitive behavior secondary measures. Altered SRS-2 scores were associated with increased saliva oxytocin concentrations. Additionally, oxytocin significantly increased time spent viewing dynamic social compared to geometric stimuli and the eyes of angry, happy and neutral expression faces. There were no adverse side-effects of oxytocin treatment. Overall, results demonstrate that a 6-week intranasal oxytocin treatment administered every other day and followed by positive social interactions can improve clinical, eye-tracking and questionnaire-based assessments of symptoms in young autistic children.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChinese Clinical Trial Registry (approved by WHO): ChiCTR1900023774Funding StatementThis work was supported by: Key Technological Projects of Guangdong Province Development of New Tools for Diagnosis and Treatment of Autism grant 2018B030335001 (KMK) ;UESTC High-end Expert Project Development grant Y0301902610100201 (KMK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of CMCCH affiliated to the University of Electronic Science and Technology of China (number 201983) as well as the general ethics committee of the University (number 1420190601). Parents or legal guardians of all participants provided written informed consent and the trial was pre-registered (Chinese Clinical Trial Registry: ChiCTR1900023774 in Chinese and in English).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for the Tables and Figures in the main paper will be provided in the final published version after peer review